Pharmacogenomics and personalized use of drugs

Current Topics in Medicinal Chemistry

Volumn 8, Issue 18, 2008, Pages 1573-1579

  Wang, Jing Fang ^a,b   Wei, Dong Qing ^a,c   Chou, Kuo Chen ^c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c GORDON LIFE SCIENCE INSTITUTE   (United States)

Author keywords

Drug metabolism; Personalized use of drugs; Pharmacogenomics; Single nucleotide polymorphisms

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ANTIRETROVIRUS AGENT; CHOLINESTERASE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; GLYCOPROTEIN P; ISONIAZID; MULTIDRUG RESISTANCE PROTEIN 1; THIOPURINE METHYLTRANSFERASE; CYTOCHROME B;

BINDING SITE; DRUG ACETYLATION; DRUG EFFICACY; DRUG METABOLISM; DRUG USE; ENZYME BINDING; ENZYME STRUCTURE; ETHNIC GROUP; GENETIC VARIABILITY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LIGAND BINDING; METHYLATION; NUCLEIC ACID BASE SUBSTITUTION; PHARMACOGENOMICS; PHASE 1 DRUG METABOLISM; PHASE 2 DRUG METABOLISM; PHENOTYPE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG THERAPY; GENOTYPE; HUMAN GENOME; METHODOLOGY; PHARMACOGENETICS; PROTEIN CONFORMATION;

CYTOCHROMES B; DRUG DESIGN; DRUG THERAPY; GENOME, HUMAN; GENOTYPE; HUMANS; MODELS, MOLECULAR; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN CONFORMATION;

EID: 59149104827     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608786786534     Document Type: Review

References (60)

1. Vogel, F. Moderne probleme der humangenetik. Ergebn. Inn. Med. Kinderheilk. 1959, 12, 52-60.
2. Kalow, W.; Tang, B. K.; Endrenyi, I. Hypothesis: comparison of inter-and-intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998, 8, 283-289.
3. Roche, O. S. P.; Zuegge, J.; Guba, W.; Kansy, M.; Alanine, A.; Bleicher, K.; Danel, F.; Gutknecht, E. M.; Rogers-Evans, M.; Neidhart, W.; Stalder, H.; Dillon, M.; Sjogren, E.; Fotouhi, N.; Gillespie, P.; Goodnow, R.; Harris, W.; Jones, P.; Taniguchi, M.; Tsujii, S.; von der Saal, W.; Zimmermann, G.; Schneider, G. Development of a virtual screening method for identification of "Frequent Hitters" in compound libraries. J. Med. Chem. 2002, 45, 137-142.
4. Weinshiboum, R. Inheritance and drug respons. N. Engl. J. Med. 2003, 348, 529-537.
5. Gonzalez, F. J.; Vilbosis, F.; Hardwick, J. P. Human debrisoquine 4-hydroxylase (CYP2D1): cDNA and deduced amino acide sequence and assignment of the CYP2D locus of chromosome 22. Genomics 1988, 2, 174-181.
6. Kiso, M.; Mitamura, K.; Sakai-Tagawa, Y.; Shiraishi, K.; Kawakami, C.; Kimura, K.; Hayden, F. G.; Sugaya, N.; Kawaoka, Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364, 759-765.
7. Johansson, I.; Lundqvist, E.; Bertilsson, L. Inherited amplification of an active gene in the P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 1993, 90, 112825-112829.
8. Eichelbaum, M.; Spannbrucker, N.; Steincke, B.; Dengler, H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol. 1979, 16, 183-187.
9. Mahgoub, A.; Idle, J. R.; Dring, L. G.; Lancaster, R.; Smith, R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977, 2, 584-590.
10. Wang, J. F.; Wei, D. Q.; Li, L.; Zheng, S. Y.; Li, Y. X.; Chou, K. C. 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. Biochem. Biophys. Res. Commun. 2007, 355, 513-519.
11. Chou, K. C. Review: Structural bioinformatics and its impact to biomedical science. Curr. Med. Chem. 2004, 11, 2105-2134.
12. Chou, K. C.; Wei, D. Q.; Du, Q. S.; Sirois, S.; Zhong, W. Z. Review: Progress in computational approach to drug development against SARS. Curr. Med. Chem. 2006, 13, 3263-3270.
13. Chou, K. C.; Jones, D.; Heinrikson, R. L. Prdeiction of the tertiary structure and substrate binding site of caspase-8. FEBS Lett. 1997, 419, 49-54.
14. Chou, K. C.; Tomasselli, A. G.; Heinrikson, R. L. Prediction of the tertiary structure of a caspase-9/inhibitor complex. FEBS Lett. 2000, 470, 249-256.
15. Zhang, R.; Wei, D. Q.; Du, Q. S.; Chou, K. C. Molecular modeling studies of peptide drug candidates against SARS. Med. Chem. 2006, 2, 309-314.
16. Chou, K. C.; Watenpaugh, K. D.; Heinrikson, R. L. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator. Biochem. Biophys. Res. Commun. 1999, 259, 420-428.
17. Tarricone, C.; Dhavan, R.; Peng, J.; Areces, L. B.; Tsai, L. H.; Musacchio, A. Structure and regulation of the Cdk5-p25 (Nck5a) complex. Mol. Cell 2001, 8, 657-669.
18. Zhang, J.; Luan, C. H.; Chou, K. C.; Johnson, G. V. W. Identification of the N-terminal functional domains of Cdk5 by molecluar truncation and computer modeling. Proteins 2002, 48, 447-453.
19. Chou, J. J.; Matsuo, H.; Duan, H.; Wagner, G. Solution structure of the RAIDD CARD and model for CARD/CARD interaction in caspase-2 and caspase-9 recruitment. Cell 1998, 94, 171-180.
20. Chou, K. C.; Howe, W. J. Prediction of the tertiary structure of the beta-secretase zymogen. Biochem. Biophys. Res. Commun. 2002, 292, 702-708.
21. Chou, K. C.; Wei, D. Q.; Zhong, W. Z. Binding mechansim of coronavirus main proteinase with lignads and its implication to drug design against SARS. Biochem. Biophys. Res. Commun. 2003, 308, 148-151.
22. Chou, K. C. Modeling extracellular domains of GABA-A receptors: subtypes 1, 2, 3, and 5. Biochem. Biophys. Res. Commun. 2004, 316, 636-642.
23. Chou, K. C. Insights from modeling the tertiary structure of BACE2. J. Proteome. Res. 2004, 3, 1069-1072.
24. Chou, K. C. Insights from modeling three-dimensional structures of the human potassium and sodium channels. J. Proteome Res. 2004, 3, 856-861.
25. Chou, K. C. Molecular therapeutic target for type-2 diabetes. J. Proteome Res. 2004, 3, 1284-1288.
26. Chou, K. C. Insights from modeling the 3D structure of the extracellular domain of alpha 7 nicotinic acetylcholine receptor. Biochem. Biophys. Res. Commun. 2004, 319, 433-438.
27. Chou, K. C. Modeling the tertiary structure of human cathepsin-E. Biochem. Biophys. Res. Commun. 2005, 331, 56-60.
28. Chou, K. C. Coupling interaction between thromboxane A2 receptor and alpha-13 subunit of guanine nucleotide-binding protein. J. Proteome Res. 2005, 4, 1681-1686.
29. Chou, K. C. Insights from modeling the 3D structure of DNACBF3b complex. J. Proteome Res. 2005, 4, 1657-1660.
30. Wei, D. Q.; Du, Q. S.; Sun, H.; Chou, K. C. Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands. Biochem. Biophys. Res. Commun. 2006, 344, 1048-1055.
31. Du, Q. S.; Wang, S. Q.; Jiang, Z. Q.; Gao, W. N.; Li, Y.; Wei, D. Q.; Chou, K. C. Application of bioinformatics and distorted key theory to find drug candidaties against SARS. Med. Chem. 2005, 1, 209-221.
32. Du, Q. S.; Wang, S. Q.; Wei, D. Q.; Sirois, S.; Chou, K. C. Molecular modeling and chemical modification for finding peptide inhibitor against SARS CoV Mpro. Anal. Biol. 2005, 337, 262-270.
33. Du, Q. S.; Wang, S. Q.; Zhu, Y.; Wei, D. Q.; Guo, H.; Sirois, S.; Chou, K. C. Cleavage mechansim of polyprotein by SARS CoV Mpro and chemical modification of octapeptide. Petidies 2004, 25, 1857-1864.
34. Gan, Y. R.; Huang, H.; Huang, Y. D.; Rao, C. M.; Zhao, Y.; Liu, J. S.; Wu, L.; Wei, D. Q. Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase. Petidies 2006, 27, 622-625.
35. Sirois, S.; Wei, D. Q.; Chou, K. C.; Du, Q. S. Assessment of databases and chemical libraries for their druggability. Comput. Biol. Chem. 2005, 29, 55-67.
36. Sirois, S.; Wei, D. Q.; Du, Q. S.; Chou, K. C. Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points. J. Chem. Inf. Comput. Sci. 2004, 44, 1111-1128.
37. Wei, H. C.; Zhang, R.; Wang, C. F.; Zheng, H. Q.; Chou, K. C.; Wei, D. Q. Molecular insights of SAH enzyme catalysis and implication for inhibitor design. J. Theor. Biol. 2007, 244, 692-702.
38. Blum, M.; Grant, D. M.; McBride, W.; Heim, M.; Meyer, U. A. Human arylamine N-acetyl-transferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990, 9, 193-203.
39. Baldwin, E. T.; Bhat, T. N.; Gulnik, S.; Hosur, M. V.; Sowder, R. C.; Cachau, R. E.; Collin, J.; Silva, A. M.; Erickson, J. W. Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. Proc. Nat. Acad. Sci. USA 1993, 90, 6796-6800.
40. Remy, C. N. Metabolism of thiopyrimidines and thiopurines: Smethylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J. Biol. Chem. 1963, 238, 1078-1161.
41. Woodson, L. C.; Weinshilboum, R. M. Human kidney thiopurine methyltransferase: purification and biochemical properties. Biochem. Pharmacol. 1983, 32, 819-845.
42. Weinshilboum, R. M.; Sladek, S. L. Mercaptopurine pharmacogenetics: monogenic inheritace of erythrocyte thiopurine methyltransferase activity. Ann. J. Human Genet. 1980, 32, 193-203.
43. Collie-Duquid, E. S.; Pritchard, S. C.; Powrie, R. H.; Sludden, J.; Collier, D. A.; Li, T.; McLeod, H. L. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999, 9, 37-42.
44. Tai, H. L.; Krynetski, E. Y.; Schuete, E. G. Enhanced proteolysis of thiopurine S-methytransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechansims for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. USA 1997, 94, 6444-6449.
45. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92, 1295-1597.
46. Choo, E. F.; Leake, B.; Wandel, C.; Imamura, H.; Wood, A. J.; Wilkinson, G. R.; Kim, R. B. Pharmacological inhibition of Pglycoprotein transpot enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 2000, 28, 655-715.
47. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M. M.; Pastan, I.; Willingham, M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 1987, 84, 7735-7743.
48. Ameyaw, M. M.; Regateiro, F.; Li, T.; Liu, X.; Tariq, M.; Mobarek, A.; Thornton, N.; Folayan, G. O.; Githanga, J.; Indalo, A.; Ofori-Adjei, D.; Price-Evans, D. A.; McLeod, H. L. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001, 11, 217-221.
49. McLeod, H. Pharmacokinetic differences between ethnic groups. Lancet 2002, 359, 78-81.
50. Hoffmeyer, S.; Burk, O.; van Richter, O.; Arnold, H. P.; Brockmoller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M.; Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: mutiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 2000, 97, 3473-3478.
51. Fellay, J.; Marzolini, C.; Meaden, E. R.; Back, D. J.; Buclin, T.; Chave, J. P.; Decosterd, L. A.; Furrer, H.; Opravil, M.; Pantaleo, G.; Retelska, D.; Ruiz, L.; Schinkel, A. H.; Vernazza, P.; Eap, C. B.; Telenti, A. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002, 359, 30-36.
52. Schaeffeler, E.; Eichelbaum, M.; Brinkmann, U. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001, 358, 383-387.
53. Chou, K. C.; Shen, H. B. Cell-PLoc: A package of web-servers for predicting subcellular localization of proteins in various organisms. Nat. Protoc. 2008, 3, 153-162.
54. Gardy, J. L.; Spencer, C.; Wang, K.; Ester, M.; Tusnady, G. E.; Simon, I.; Hua, S.; DeFays, K.; Lambert, C.; Nakai, K.; Brinkman, F. S. PSORT-B: Improving protein subcellular localization prediction for Gram-negavie bacteria. Nucleic Acids Res. 2003, 31, 3613-3617.
55. Chou, K. C.; Shen, H. B. MemType-2L: A Web server for predicting membrane proteins and their types by incorporating evolution information through Pse-PSSM. Biochem. Biophys. Res. Commun. 2007, 360, 339-345.
56. Shen, H. B.; Chou, K. C. EzyPred: A top-down approach for predicting enzyme functional classes and subclasses Biochem. Biophys. Res. Comm. 2007, 364, 53-59.
57. Shen, H. B.; Chou, K. C. HIVcleave: a web-server for predicting HIV protease cleavage sites in proteins Anal. Biochem. 2008, 375, 388-390.
58. Chou, K. C.; Shen, H. B. ProtIdent: A web server for identifying proteases and their types by fusing functional domain and sequential evolution information. Biochem. Biophys. Res. Commun. 2008, 376, 321-325.
59. Chou, K. C.; Shen, H. B. Signal-CF: a subsite-coupled and window-fusing approach for predicting signal peptides. Biochem. Biophys. Res. Commun. 2007, 357, 633-640.
60. Shen, H. B.; Chou, K. C. Signal-3L: a 3-layer approach for predicting signal peptide. Biochem. Biophys. Res. Commun. 2007, 363, 297-303.